In the pivotal CARTITUDE-1 study, patients treated with ciltacabtagene autoleucel demonstrated an ORR of 98% (95/97 95% CI: 92.7-99.7),a an sCR of (76/97 95% CI: 68.8-86.1),ab a VGPR of 17% (16/97 95% CI: 9.7-25.4),a and a PR of 3% (3/97 95% CI: 0.6-8.8).a The mDOR was 21.8 months (95% CI: 21.8-NE).1

CI=confidence interval; NE=not estimable; ORR=overall response rate; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

aBased on a median duration of follow-up of 18 months.

bAll complete responses were stringent complete responses.

Efficacy Study design

Pivotal CARTITUDE-1 Study1-3

Phase 1b/2, open-label, multicenter trial of 97 adult patients with relapsed or refractory multiple myelomaa

Primary objectives

PHASE 1B

Characterize safety and confirm Phase 2 dose

PHASE 2

Evaluate efficacy:

  • ORR (primary endpoint)
  • sCR, CR, VGPR, DOR, TTR, TT≥CR, MRD-, PFS, OS (select secondary endpoints)
  • The median time from leukapheresis to product availability was 32 days (range, 27-66 days)
  • Of the 97 patients, 17 patients (18%) received ciltacabtagene autoleucel that did not meet product release specifications due to manufacturing failure or that contained insufficient data to confirm product release specifications

CAR=chimeric antigen receptor; CR-complete response; DOR=duration of response; MRD=minimal residual disease negativity; ORR=overall response rate; OS=overall survival; PFS=progression free survival; sCR=stringent complete response; TT≥CR=time to complete response or better; TTR=time to response; VGPR=very good partial response.

aSee key eligibility criteria below.

bOne patient received retreatment with ciltacabtagene autoleucel.

Key eligibility criteria

  • Diagnosis of multiple myeloma per IMWG criteria, with measurable disease
  • ≥3 previous lines of therapy (or double refractory) to a proteasome inhibitor and an immunomodulatory agent
  • Previous treatment with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
  • Disease progression per IMWG criteria within 12 months of last line of therapy
  • ECOG performance status 0-1a

Exclusion criteria

  • Known active or prior history of significant CNS disease including CNS multiple myeloma
  • Plasma cell leukemia
  • Allogeneic stem cell transplant within 6 months before apheresis or ongoing treatment with immunosuppressants
  • Creatinine clearance <40 mL/min
  • Absolute lymphocyte concentration <300/μL
  • Absolute neutrophil count <750 cells/mm3
  • Platelet count <50,000/mm3
  • Hepatic transaminases >3x the upper limit of normal
  • Cardiac ejection fraction <45%
  • Active serious infection
  • Prior treatment with CAR-T directed at any target
  • Prior therapy that is targeted to BCMA

BCMA=B cell maturation antigen; CD38=cluster of differentiation 38; CNS=central nervous system; ECOG=Eastern Cooperative Oncology Group; IMWG=International Myeloma Working Group.

aECOG performance status at baseline was 2 in 4% of patients.

CARTITUDE-1 study: select baseline characteristics (N=97)1-3

DEMOGRAPHICS
Age, range (median) 43-78 years (61)
Male (n) 59% (57)
African American (n) 18% (17)
ECOG performance status 0 (n) 40% (39)
ECOG performance status 1 (n) 56% (54)
ECOG performance status 2 (n) 4% (4)
DISEASE
High-risk cytogenetic profile (n)a 24% (23)
Extramedullary plasmacytomas ≥1 (n) 13% (13)b
Tumor BCMA expression ≥50% (n) 92% (57)c
CrCl <45mL/min (n) 3% (3)
PRIOR TREATMENTS
Time since diagnosis, median 5.9 years
Prior lines of therapy, median (range) 6 (3-18)
Triple-class exposed (n)d 100% (97)
Penta-exposed (n)e 84% (81)
Triple-class refractory (n)d 88% (85)
Penta-refractory (n)e 42% (41)
Refractory to last line of therapy (n) 99% (96)
Prior autologous transplant (n) 90% (87)
Previous allogeneic stem cell transplant (n) 8% (8)

BCMA=B cell maturation antigen; CD38=cluster of differentiation 38. CrCl=creatinine clearance; ECOG=Eastern Cooperative Oncology Group.

aBased on the presence of del(17p), t(14;16), or t(4;14).

bAdditional 6 patients had a soft-tissue component of a bone-based plasmacytoma (total plasmacytomas, 19.6%).

cDenominator n=62, the number of evaluable samples; BCMA expression detected in all evaluable samples.

d≥1 proteasome inhibitor, ≥1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody.

e≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and 1 anti-CD38 monoclonal antibody.

Deep responses

Nearly every patient achieved a clinical response

98% overall response rate (N=97; primary endpoint)a1

ORR Chart
  • Median time to first response was 1 month (range, 0.9-10.7)

ORR=overall response rate; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

aBased on a median duration of follow-up of 18 months.

bAll complete responses were stringent complete responses.

Durable responses

Median duration of response demonstrated in CARTITUDE-1a1

mDOR image

CI=confidence interval; mDOR=median duration of response; NE=not estimable; sCR=stringent complete response

abased on a median duration of follow-up of 18 months.

Learn more about CARVYKTI
Register to be contacted by a representative